Evidence map›Paper›PMID 24550830›Full record

ReviewFrontiers in pharmacology2014

The role of CaMKII regulation of phospholamban activity in heart disease.

Alicia Mattiazzi, Evangelia G Kranias

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in pharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers.

0numbers the graph read from it
0cells of the map it votes in
75citing papers in PubMed
5.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

75 citing papers in PubMed, 144 citations in OpenAlex.

  1. Article
  2. Review
  3. PMArchives of toxicology · 2026
    Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. CaInflammation and regeneration · 2025
    Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article

15 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Alicia MattiazziFacultad de Medicina, Centro de Investigaciones Cardiovasculares, Conicet La Plata-Universidad Nacional de La Plata La Plata, Argentina.
Evangelia G KraniasDepartment of Pharmacology and Cell Biophysics, College of Medicine, University of Cincinnati Cincinnati, OH, USA.
University of Cincinnati · US

Funding

Cardiac Sarcoplasmic Reticulum Calcium Cycling ProteinsR01HL064018 · NHLBI · UNIVERSITY OF CINCINNATI · PI KRANIAS, EVANGELIA G · 2000 to 2017
$6.8M
TARGETED ABLATION AND ALTERATION OF MOUSE PHOSPHOLAMBANR01HL026057 · NHLBI · UNIVERSITY OF CINCINNATI · PI KRANIAS, EVANGELIA G · 1985 to 2017
$5.3M
TARGETED ABLATION AND ALTERATION OF PHOSPHOLAMBANR37HL026057 · NHLBI · UNIVERSITY OF CINCINNATI · PI KRANIAS, EVANGELIA G · 1994 to 2003
$1.1M
NHLBI NIH HHS R01 HL026057NHLBI NIH HHS R01 HL064018NHLBI NIH HHS R37 HL026057
6 · The paper itself

Abstract

Phospholamban (PLN) is a phosphoprotein in cardiac sarcoplasmic reticulum (SR) that is a reversible regulator of the Ca(2) (+)-ATPase (SERCA2a) activity and cardiac contractility. Dephosphorylated PLN inhibits SERCA2a and PLN phosphorylation, at either Ser(16) by PKA or Thr(17) by Ca(2) (+)-calmodulin-dependent protein kinase (CaMKII), reverses this inhibition. Through this mechanism, PLN is a key modulator of SR Ca(2) (+) uptake, Ca(2) (+) load, contractility, and relaxation. PLN phosphorylation is also the main determinant of β1-adrenergic responses in the heart. Although phosphorylation of Thr(17) by CaMKII contributes to this effect, its role is subordinate to the PKA-dependent increase in cytosolic Ca(2) (+), necessary to activate CaMKII. Furthermore, the effects of PLN and its phosphorylation on cardiac function are subject to additional regulation by its interacting partners, the anti-apoptotic HAX-1 protein and Gm or the anchoring unit of protein phosphatase 1. Regulation of PLN activity by this multimeric complex becomes even more important in pathological conditions, characterized by aberrant Ca(2) (+)-cycling. In this scenario, CaMKII-dependent PLN phosphorylation has been associated with protective effects in both acidosis and ischemia/reperfusion. However, the beneficial effects of increasing SR Ca(2) (+) uptake through PLN phosphorylation may be lost or even become deleterious, when these occur in association with alterations in SR Ca(2) (+) leak. Moreover, a major characteristic in human and experimental heart failure (HF) is depressed SR Ca(2) (+) uptake, associated with decreased SERCA2a levels and dephosphorylation of PLN, leading to decreased SR Ca(2) (+) load and impaired contractility. Thus, the strategy of altering SERCA2a and/or PLN levels or activity to restore perturbed SR Ca(2) (+) uptake is a potential therapeutic tool for HF treatment. We will review here the role of CaMKII-dependent phosphorylation of PLN at Thr(17) on cardiac function under physiological and pathological conditions.

Indexed as

acidosisCaMKIIheart failureischemia/reperfusion injurymyocardiumPLN regulation

Identifiers

PMID24550830
PMCPMC3913884
OpenAlexW2079974543

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.